If you only skimmed the 2025 debate around Varex Imaging, you would have seen bulls talking up India expansion and photon counting, while bears worried about shrinking medical demand and customer concentration. For Varex Imaging shareholders, the return from the start of the year was 58.1%, including dividends. If you had been deciding on 1 January with just those clashing narratives in hand, what would you have focused on most?
Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.
Varex Imaging has already moved. Pinpoint other ways to investigate the theme among 34 healthcare AI stocks.
The Two Varex Imaging Stories Investors Had To Weigh
The shares cost US$11.65 at the start of the period, and Varex Imaging sat between two sharply different but reasonable stories about its future.
The bullish narrative put fair value at US$16.6, framed around India manufacturing and photon counting technology. Supporters focused on assumptions such as 4.1% annual revenue growth and profit margins moving from a loss of 16.1% toward 12.3%.
The bearish view set fair value at US$10 and leaned on healthcare cost controls and customer concentration risks. That camp still used 3.6% annual revenue growth and the same margin shift, but viewed those expectations as potentially too optimistic.
What The Results Changed For Varex Imaging
The biggest development came after the period in focus. Teledyne Technologies agreed to acquire Varex Imaging for about US$1.1b, or US$18.90 per share in cash, which supported the optimistic camp that saw higher value in the business. Quarterly figures also gave bulls fresh support as revenue reached US$210.5m and net income turned to a profit of US$15.7m, lifting net margin to 7.5%.
The whole episode turned on whether Varex Imaging could shift from losses to sustainable profitability. When assessing another company with a similar debate, focus on the direction of net margin and whether positive earnings arrive on schedule compared with the original thesis.
Where Expectations Sit In Varex Imaging Now
The Varex Imaging share price is now US$18.42, not far from the agreed US$18.90 Teledyne bid. As a result, the market focus has shifted from turnround potential to deal completion risk. That move in price reflects a very different question than at the start of the year.
Business results still matter. Revenue reached US$210.5m and net margin moved from a loss of 43.9% in Q3 2025 to a 7.5% profit in Q3 2026. The key assumption to test is how repeatable that profitability level is.
We value every stock in the world, every day. See what our valuation says Varex Imaging is worth now.
Looking Beyond Varex Imaging
Varex Imaging lives in hardware, turning complex imaging tech into installed equipment. Your next question could be what happens once those machines are running.
Hospitals then face a different hurdle. They want surgeons who can match that precision inside the body.
One specialist company built surgical robots around minimally invasive procedures. It wraps them in training tools, performance tracking and ongoing software support.
That mix turns each machine into a long-term learning platform. If imaging demand reflects procedure volumes, this kind of ecosystem may shape how often those scans lead to surgery.
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 23% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com